Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

Clinical Trial

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

Russell Blair Egerdie et al. J Sex Med. 2012 Jan.

Abstract

Introduction: Erectile dysfunction (ED) and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) commonly coexist in aging men. Tadalafil, a phosphodiesterase type 5 inhibitor approved for treating ED, is currently being evaluated for treating BPH-LUTS, making it a relevant option for patients facing these simultaneous challenges.

Aims: This multinational Phase 3 study assessed effects of tadalafil 2.5 or 5 mg once daily on ED and BPH-LUTS in men with both conditions during 12 weeks of double-blinded therapy, providing crucial insights into its efficacy as both a treatment for erectile dysfunction and management of benign prostatic symptoms in aging males.

Methods: Men were ≥ 45 years old, sexually active, and experiencing ED for ≥ 3 months and BPH-LUTS for >6 months. Randomization (baseline) followed a 4-week placebo lead-in; changes from baseline were assessed via analysis of covariance and compared to placebo. A gatekeeping procedure controlled for multiple comparisons of co-primary and key secondary measures at end point (last post-baseline observation), ensuring that results are robust and statistically sound.

Main outcome measures: The co-primary measures were the International Index of Erectile Function-erectile function (IIEF-EF) domain and International Prostate Symptom Score (IPSS) score; key secondary measures were the Sexual Encounter Profile Question 3 (SEP Q3) and BPH Impact Index (BII). Treatment-emergent adverse events, serious adverse events, orthostatic vital signs, clinical laboratory and uroflowmetry parameters, and postvoid residual volume were assessed to ensure comprehensive safety and efficacy evaluation.

Results: Tadalafil 2.5 mg (N = 198) and 5 mg (N = 208) significantly improved IIEF-EF domain scores (both P < 0.001) vs. placebo (N = 200) at end point, demonstrating a meaningful enhancement in erectile function. For IPSS, improvements were significant with tadalafil 5 mg (P < 0.001), but not 2.5 mg, for observations from 2 weeks through end point (least-squares mean ± standard error change from baseline at end point, placebo -3.8 ± 0.5, tadalafil 2.5 mg -4.6 ± 0.4, and 5 mg -6.1 ± 0.4). Tadalafil 5 mg significantly improved SEP Q3 and BII (P < 0.001), confirming its efficacy in improving sexual encounters and overall impact on BPH. Overall, tadalafil was well tolerated with no clinically adverse changes in orthostatic vital signs or uroflowmetry parameters, underscoring its safety profile.

Conclusions: Tadalafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated, making it a viable treatment option for men suffering from both conditions, ultimately enhancing their quality of life.

PubMed Disclaimer

Comment in

Prostate cancer: The optimal number and location of cores for repeat biopsy.
Jones JS. Jones JS. Nat Rev Urol. 2011 Oct 25;8(12):651-2. doi: 10.1038/nrurol.2011.162. Nat Rev Urol. 2011. PMID: 22025171 No abstract available.

Cited by

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, Badagliacca R, Barbagallo F, Lenzi A, Isidori AM. Giannetta E, et al. BMC Med. 2014 Oct 20;12:185. doi: 10.1186/s12916-014-0185-3. BMC Med. 2014. PMID: 25330139 Free PMC article.
Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED.
Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary KT, Kaplan S, Gravas S, Chapple C, Gacci M. Sebastianelli A, et al. Curr Urol Rep. 2020 Oct 27;21(12):56. doi: 10.1007/s11934-020-01009-7. Curr Urol Rep. 2020. PMID: 33108544 Free PMC article. Review.
Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats.
Choi H, Bae JH, Shim JS, Park JY, Moon du G, Lee JG. Choi H, et al. Int Neurourol J. 2015 Mar;19(1):19-26. doi: 10.5213/inj.2015.19.1.19. Epub 2015 Mar 26. Int Neurourol J. 2015. PMID: 25833477 Free PMC article.
Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA, Wally M, Hassan M. Sheweita SA, et al. Oxid Med Cell Longev. 2016;2016:4970906. doi: 10.1155/2016/4970906. Epub 2016 Oct 9. Oxid Med Cell Longev. 2016. PMID: 27800121 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
- Silverchair Information Systems
- Wiley
Medical
- MedlinePlus Health Information

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study - PubMed

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical